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Abstract 
Post vasectomy semen analysis (PVSA) is the procedure used to establish whether sperm are present in the 
semen following a vasectomy. PVSA is presently carried out by a wide variety of individuals, ranging from 
doctors and nurses in General Practitioner (GP) surgeries to specialist scientists in andrology laboratories, with 
highly variable results.  
Key recommendations are that: 1) PVSA should take place a minimum of 12 weeks after surgery and after a 
minimum of 20 ejaculations; 2) Laboratories should routinely examine samples within 4 hours of production if 
assessing for presence of sperm. If non-motile sperm are observed, further samples must be examined within 
1 hour of production; 3) Assessment of a single sample is acceptable to confirm vasectomy success if all 
recommendations and laboratory methodology are met and no sperm are observed. Clearance can then be 
given; 4) The level for special clearance should be <100,000/ml non-motile sperm. Special clearance cannot be 
provided if any motile sperm are observed and should only be given after assessment of two samples in full 
accordance with methods contained within these guidelines. 
Surgeons are responsible both pre-operatively and post-operatively for the counselling of patients and their 
partners regarding complications and the possibility of late recanalisation after clearance.  
These 2016 guidelines replaces the 2002 British Andrology Society (BAS) laboratory guidelines and should be 
regarded as definitive for the UK in the provision of a quality PVSA service, accredited to ISO 15189:2012, as 
overseen by the United Kingdom Accreditation Service (UKAS). 
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INTRODUCTION 
Post vasectomy semen analysis (PVSA) is the laboratory procedure used to establish whether sperm are 
present in the semen following a vasectomy. As such, PVSA indicates whether surgery has been successful to 
achieve male sterilisation. 
PVSA continues to be carried out by a wide variety of individuals with different levels of training. This ranges 
from doctors and nurses in GP surgeries to specialist scientists in dedicated andrology laboratories. PVSA may 
also be performed in general pathology laboratories. Consequently, the test quality and control of the 
procedure is variable, which is clearly not acceptable for a “Yes/No” indicator of surgical success.  
In the UK, the move towards laboratory accreditation overseen by the United Kingdom Accreditation Service 
(UKAS) to the international standard ISO 15189:2012, is driving the quality of the PVSA process forward. Only 
laboratories meeting this analytical standard should be considered as providing the necessary reliability of 
result to confirm successful vasectomy.  
In 2002 the British Andrology Society (BAS) published a set of laboratory guidelines for PVSA [1]. Advances in 
technique options, observations of areas where uncertainty exists and compliance with the ISO 15189:2012 
standard, now make additions to the 2002 BAS guidelines desirable. Revisions include clarifying factors around 
when and how to test and the number of samples that should be examined.  
These 2016 guidelines have been agreed and accepted across the three major groupings and co-author 
professional bodies for the field as best practice providing for standardisation of seminal analysis protocols 
and reporting of results. Crucially it should be noted that they are not only clinical recommendations but also 
take into account good laboratory practice and the accuracy of diagnosis. As such they supercede any prior 
guidelines published for the UK. The guidelines do not deal with the counselling of patients or discuss the 
indications for male sterilisation, for which compliance with the Faculty of Sexual & Reproductive Healthcare 
(FSRH) clinical guidance for male and female sterilization is recommended[2].  
It is always important for patients to be warned that a vasectomy may apparently fail at any time, though the 
actual chance of this is rare, at less than 1% if correctly performed [3-8], with some reports suggesting that 
temporary reappearance of sperm may occur a year after clear PVSA [9].  
Failures can be classed into early and late recanalisation. Recanalisation is considered to have occurred where, 
after an initial azoospermic sample, there is a rapid increase in sperm numbers [10 11] . These are suggested 
to comprise the major category of vasectomy failures [12]. The potential for late recanalisation has been 
reported to be around 0.04% to 1% [4 13].  
Measurements of vasectomy failure are complex to interpret, as many are only discovered after an adverse 
outcome, i.e. occurrence of a pregnancy. It should also be recognized that no data exist relating to women 
who may seek pregnancy terminations after this unexpected outcome, perhaps without telling their partner. 
As pregnancies have been confirmed to occur even after repeated azoospermic samples, [14] due caution 
around the meaning of a PVSA result should always be noted in reports. The patient should be provided with 
information from his clinician regarding the likelihood of a successful vasectomy operation and the possibility 
of recanalisation. It is recommended that such information should be given both verbally and in writing [12].   
 
FERTILITY OF RESIDUAL SPERM POST SURGERY   
Ejaculates may contain potentially fertile sperm immediately after vasectomy [15], and patients should 
continue with contraceptive precautions until successful vasectomy has been confirmed. This has been 
extensively discussed in the 2002 BAS guidelines [1] and by the FSRH [2].  
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POST VASECTOMY SEMEN SAMPLES  
Scheduling of sample testing 
The time between the vasectomy and the PVSA has been widely discussed without agreement, with some 
publications even suggesting a wait of up to 6 months before first analysis [16].   However, the majority of 
published literature suggests a minimum number of weeks before testing of between 12 [6 11 16 17], 14 [18 
19] and 16 weeks [1 20].   Decreased patient compliance has been noted with longer intervals [6 17 20]. 
The earlier the PVSA testing occurs, the more the likelihood increases of a false positive result. This may be 
due to an inflammatory reaction and/or temporary bruising within the testis.  These is also evidence that early 
recanalisation can occur within the first few weeks following a vasectomy, and this may be more common 
after certain techniques[12] and may be transient [21]. Testing too early may also cause problems with 
analysis due to high sample viscosity, presence of residual (usually non-motile) sperm and raised levels of 
round cells that may mask sperm presence. Therefore, the desire to perform prematurely early PVSAs has to 
be balanced against the increased patient inconvenience and also the workload / cost to the laboratory (e.g. 
[16 17 22 23]) as repeat tests would be required for accurate confirmatory diagnosis. 
There is a consensus that ‘sufficient ejaculations’ should take place between the vasectomy and the PVSA, 
since ejaculatory frequency will affect time to azoospermia. [1 11 24].   Men with fewer than 3 ejaculations per 
week have been reported to reach azoospermia around 5 weeks later than those with a higher number of 
ejaculations [25]. It has also been reported that azoospermia may not be achieved until 60 ejaculates for some 
individuals [25].   However, systematic review data indicates that by 20 ejaculates, 80% of men should show 
azoospermia or sperm numbers beneath detectable levels [11] .  It is therefore recommended that knowing 
the  number of ejaculates is important, though some authors have debated this point [24].  
The recommendation is Grade B due to robust evidence, noting that it is surprising and disappointing that no 
conclusive multi-centre study has yet occurred for such a prevalent procedure. 
Recommendation 1: PVSA should take place a minimum of 12 weeks after surgery and after a minimum of 
20 ejaculations. 
 
Pre-Assessment 
Sample collection instructions 
The laboratory staff should ensure that the person requesting the PVSA test is provided with clear ‘user 
information’ in the form of written instructions for sample collection. Sample production should be arranged 
on an appointment basis to ensure the laboratory has sufficient time for each assessment to be completed 
within recommended analytical time frames.  
The specimen container 
Gamma-irradiated and mouse embryo assay (MEA)-tested specimen containers are recommended for use, 
together with CE-marking for containers manufactured in Europe. However, none of these tests confirm the 
level of sperm non-toxicity.  Specimen containers should therefore additionally be confirmed as non-toxic to 
sperm via an in-house sperm toxicity bioassay [26]. Confirmation of sperm non-toxicity should also apply to all 
consumables used in the PVSA process that come in to contact with the sample, e.g. any tubes, slides, 
coverslips and pipette tips. Traceable sperm toxicity testing is required for each new batch and make of item, 
in accordance with ISO 15189:2012.  
If samples are provided in unscreened specimen containers, the PVSA report will only be valid if no sperm are 
observed. If sperm are observed, and they are immotile, then no confirmation of sperm non-toxicity from the 
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specimen container can be provided. As such, the PVSA would need to be repeated in a screened specimen 
container to ascertain if motile sperm are present in the ejaculate. Use of unscreened specimen containers is 
considered a waste of resources, not least in terms of patient and laboratory time. 
Collection of the sample 
Instructions to patients 
Patients should be advised to produce a sample in accordance with guidelines for good practice e.g. [27] 29. The 
abstinence period should be between 2 and 7 days as per the latest WHO guidance [28]. 
Men should be asked to collect their entire ejaculate by masturbation. Use of coitus interruptus, condoms or 
oral production is not recommended as this can lead to sample contamination. One study reported that 9.4% 
PVSA samples were not completely collected [29], which could increase the risk of misdiagnosis if analysed. 
Strict criteria for rejection of incomplete samples should be in place, as assessment of incomplete samples will 
introduce an unacceptable level of uncertainty. However, assessment of an aliquot may be used to guide 
future management if motile sperm are present.  
Receipt of Samples 
On delivery of the semen sample to the laboratory reception, staff should ensure that the specimen container 
is clearly labelled with at least three patient identifiers (e.g. name, date of birth, and clinic number) and that 
details of sample collection are recorded, e.g. abstinence period and confirmation that the entire sample was 
collected. To achieve this, provision of clear understandable information to the patient is a pre-requisite 
alongside a checklist at the laboratory reception to confirm any factors relating to sample production. All staff 
dealing with patient contact should be trained appropriately in respecting privacy and dignity. Associated 
facilities and systems for the service should also ensure that this is recognised as an important part of 
diagnostic provision.  
Overall Guidance on Sample Procurement 
To prevent time delays or fluctuations in temperature, on-site production facilities are recommended. 
However, off-site production is acceptable provided samples are kept as close to body temperature as possible 
during transport to the laboratory. This transport should take place immediately after sample production since 
any change in temperature may affect sperm viability and motility. The elapsed time period must be stated on 
the report form. 
As the period elapsed between production and examination increases, so does the risk of sperm losing 
motility, since seminal plasma may have deleterious effects on sperm motility [30].  As such, an exposure for 
more than 1 hour may confound test results. In 2012 the American Urological Association (AUA) decided that 2 
hours between production and analysis was sufficient, stating that rather than precise motion quality, it is the 
presence or absence of motility that is important for a PVSA [31]. This 2 hour interval has been supported by 
Australian and Dutch workers [18](Royal Australasian College of Surgeons, 2009). However, the data to 
support this decision is minimal.  
The ABA, BAS and BAUS consider that presence or absence of sperm can be assessed within a 4 hour period 
post-ejaculation. However, in cases where non-motile sperm are present in the ejaculate, it is strongly 
recommended that further fresh samples should be examined within 1 hour of production to confirm absence 
of motility and/or allow vitality testing.  This requirement for a repeat sample meets the WHO 
recommendations for semen analysis [28].  
The recommendation is Grade C due to limited evidence, but having the backing of experts and the three 
professional bodies. 
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Recommendation 2a: Laboratories should routinely examine samples within 4 hours of production if 
assessing for presence of sperm. If non-motile sperm are observed, further samples must be examined 
within 1 hour of production. 
Postal / courier transport of samples 
The 2002 BAS guidelines allowed for postal delivery of samples1. However, there are no published studies to 
demonstrate process validation for detection of sperm transported in this way. Indeed it would be very 
difficult to suggest that standard postal methods would meet the necessary requirements for knowing sample 
handling and environmental control were adequate. This may also compromise ISO 15189:2012 accreditation 
as the laboratory would not have control of the process and thus cannot establish uncertainty. 
The time of production should be recorded on the specimen container, and samples should be no more than 4 
hours old on examination. If samples are over 4 hours old as stated above, there is currently insufficient data 
to validate the accuracy of any results obtained, particularly with relation to uncontrolled transport situations. 
In this situation, an observation of no sperm present must have the caveat that no accurate validation for 
transport samples is available and it is suggested that a fresh sample is provided in accordance with these 
guidelines. 
The longer the time a sample spends in transit to a laboratory, the greater the risk of sperm degradation. The 
professional bodies are therefore in agreement that actual ‘postal’ delivery of samples, with analysis times 
beyond 4 hours does not have sufficient underpinning evidence to be deemed acceptable good laboratory 
practice for an accurate diagnosis and should not be used.  It should also be highlighted that failure to follow 
guidelines may have medico-legal consequences. 
Laboratories accepting posted/couriered samples should ensure that patients understand the sample/request 
form labelling requirements and the current regulations for the transport and packaging of samples[32]. 
Patients and physicians must also be fully aware that a PVSA performed on a posted/couriered sample should 
only be used to detect the absence of sperm.  
If non-motile sperm are observed in the posted/couriered, it is mandatory that a freshly produced sample be 
examined within 1 hour of production to exclude the possibility that motile sperm are present as per 
recommendation 2. Clear communication with the patient that sperm have been found and hence another 
sample is necessary under certain higher-stringency conditions should ensure they attend to clarify their 
personal fertility situation. 
The recommendation is a Grade A recommendation as it is a requirement for acceptability of results in a 
diagnostic test. 
Recommendation 2b: Where examination of a sample occurs outside recommended parameters this must 
be clearly noted on the report and clearance should not be given. 
 
LABORATORY ASSESSMENT 
Recommended equipment 
Due to the viscous nature of semen samples, a positive displacement pipette (PDP) should be used for all 
aliquot sampling. A phase contrast microscope, with x200 and x400 magnification, is required. 
A centrifuge that can take 15ml tubes is recommended, with a rotor that has been calibrated to provide a 
3000g force for 15 minutes as per the original BAS 2002 guidelines. This is the maximum speed recommended 
by WHO for the assessment of azoospermia as higher speeds may risk damage to the sperm, such as 
decapitation, which makes their detection less likely [28]. Whilst use of 15ml conical tubes is recommended, 
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smaller volume tubes, e.g. 1.5–2.0ml tubes may be used, according to the size of the centrifuge available.  The 
centrifuge should be calibrated to metrologically accepted standard, in accordance with ISO 15189:2012. 
Sample examination 
It is recommended that samples are warmed to 37°C in an incubator, to assist the liquefaction process.  
Samples should ideally be examined once liquefaction is complete, accepting that this may not be possible, 
since PVSA samples may continue to be highly viscous. 
Two methods of examination are possible: 
1. The original 2002 BAS guidelines method.  
The sample should be mixed well and 10μl pipetted on to a clean non-toxic glass slide using a PDP and covered 
with a 22 × 22mm coverslip. This gives a suitable depth (10-20μm) to allow any motile sperm present to swim 
freely. 
 
Using phase contrast microscopy, the entire coverslip area should be examined in a systematic grid search 
pattern for the presence of sperm. 
 
If no sperm are observed, the entire semen sample should be transferred using a sterile pipette into an 
appropriate centrifuge tube and centrifuged at 3000g for 15 minutes. The entire pellet should be resuspended 
in a minimum volume of autologous seminal plasma (< 100μl) and the entire sample examined systematically 
for the presence of motile and non-motile sperm. An estimation of sperm concentration or number of sperm 
observed in each high power field (×400 magnification) should be reported. After centrifugation, the pellet 
may contain a large number of cells including germ cells, epithelial cells and leucocytes. This debris may make 
the detection of any sperm difficult and the report should state that these cells might have obscured 
observation of any sperm present. 
 
2. Large Volume Fixed Depth Slides 
Use of the fixed 100µm depth slide method avoids the need for centrifugation and has been shown to give a 
similar sperm detection level [33]. A larger volume of 25μl is transferred, using a PDP, to fixed depth slides.  
Each slide should be filled with a single continuous flow and any excess removed once the fill is complete. The 
filled slides should be stored in a 37°C, humid atmosphere for at least 15 minutes prior to examination, to 
allow non-motile sperm to reach the basal glass plane. The chamber depth of 100µm has been specifically 
designed to quantify low numbers of cells in suspension and allows any motile sperm present to swim freely.  
Use of slides with a quality assurance of dimensions, e.g. CE-mark, is required to ensure consistent sample 
volumes and fill effects. All slides and PDP tips must have passed traceable sperm toxicity testing to that 
specific batch. 
The slides should be examined using phase contrast microscopy at either x200 or x400 magnification with the 
entire slide area being examined in a systematic grid search pattern for the presence of sperm.   
 
Observations of sperm via either method 
If motile sperm are observed by either method, then a full sperm concentration and motility assessment 
should be performed according to standard WHO procedures, using an Improved Neubauer chamber count 
performed according to ‘accurate’ methods (see Section 2.11 of the WHO manual for guidance about counting 
low sperm numbers)[28]. 
 
Other methods have recently been suggested and discussed for PVSA..[34-36]. Whilst some of the suggestions 
for QA/QC are useful, methods other than those specified above are not recommended. 
 
 
Should a sample be centrifuged? 
Microscopic examination of uncentrifuged specimens has been shown to be a reliable method for PVSA, 
provided >100,000 sperm per ml are present [37]. However, whilst this laboratory technique has been 
reported to detect high numbers of sperm present in PVSA samples, establishing the accuracy of lower sperm 
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numbers would not be sufficient for medico-legal consideration.  An additional factor to consider is the 
heterogeneous nature of PVSA semen samples, which may not allow for a reliable sampling of the whole 
sample. If the 100µm large volume fixed depth slide method is not used, it is the consensus view of the 
Professional Bodies that samples should be centrifuged.  The pellet can then be assessed using small volume 
disposable slides (10μl) or standard slides as per the 2002 BAS guidelines method. 
High-viscosity Samples 
For both PVSA methods, in cases of persistent seminal viscosity, the entire ejaculate may be incubated for up 
to 1 hour with a protease such as alpha chymotrypsin as per standard protocols [38]. However, incubation 
with a protease may immobilise motile sperm present and the laboratory should highlight this on the report 
accordingly. 
The recommendation is Grade B being supported by robust evidence and also having the backing of experts 
across the three professional bodies. 
Recommendation 3: Laboratories should examine samples using either the 2002 BAS Guideline ‘coverslip 
and centrifugation’, or large volume fixed depth slide methods. If samples are treated with proteases, this 
should be highlighted on the report accordingly 
INTERNAL QUALITY CONTROL 
In order to ensure precise and accurate results from the PVSA testing laboratory, a process of internal quality 
control (IQC) is required. Day-to-day monitoring of precision and accuracy reassures users of the service that 
there is uniformity within the laboratory.  
IQC requires a central reference sample to enable direct comparisons between different laboratory staff 
performing PVSA.  Depending on the number of PVSA samples that a laboratory receives, the simplest way to 
assess IQC is to use one of these samples and perform the assessment in parallel with other members of 
laboratory staff. The results can then be compared.  Given that the primary objective is the detection of sperm, 
use of Shewhart charts is not necessary. 
As far as the authors are aware, there is presently only one external quality assurance (EQA) scheme operating 
for PVSA, but this is not accredited to an ISO standard.  An EQA scheme for PVSA should provide independent 
consensus for the presence/absence of sperm. The impracticality of providing such EQA, which should involve 
sending out sperm-free samples and samples with a very low numbers of sperm, has deterred other schemes 
being set-up nationally or internationally to date. In accordance with ISO 15189:2012 requirements, 
participation in an EQA scheme is required where both standard semen analyses and PVSA are performed by 
the same laboratory. Participation in EQA is the ideal situation for all diagnostic laboratories, however if the 
laboratory only performs PVSA it may be acceptable to perform testing if participating in an adequate Inter-
Laboratory Comparison (ILC) scheme alongside inter-operator variability assessment, so long as at least one 
participating laboratory maintains results deemed acceptable in an EQA.  For the specific scenario of PVSA all 
laboratories should establish their level of detection, via appropriate dilutions of semen, which will also help 
address uncertainty. Routine practice audit should also assist in provision of a timely and appropriate service. 
The recommendation is a Grade A recommendation as it is a requirement for accurate results in a diagnostic 
test. 
Recommendation 4: As a minimum, laboratories should participate in IQC and ILC with a laboratory which 
has known EQA standards.  Ideally laboratories should directly participate in an accredited andrology EQA 
scheme for sperm count and motility assessment. 
 
POST ASSESSMENT - THE UNCERTAINTY FACTOR 
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There are many areas where uncertainty can lead to questions about the robustness of PVSA.  
The recommendations in these guidelines aim to reduce the uncertainty.  However, unless strict sample 
rejection criteria are enforced, a higher than necessary uncertainty will impact on the PVSA. Even with strict 
adherence to guidelines, an uncertainty factor will remain, which should be reported to all users of the service. 
For example, it has been reported that a large proportion of patients (up to 25%) fail to comply with 
instructions regarding sample collection, making reliable laboratory assessment impossible, or fail to submit a 
sample in the first place[16 39 40]. 
Each PVSA laboratory should consider all areas that can impact on the uncertainty, including those within the 
laboratory. Whilst the measurement and reporting of sample volume is not routinely required, laboratories 
should report samples that exhibit either high (>10ml) or low volumes (<1 ml) as this may indicate non-
compliance in collection procedures. Such volumes should be included and highlighted in the final report to 
draw attention to this possible uncertainty. 
 
HOW MANY SAMPLES SHOULD BE ASSESSED? 
The 2002 BAS guidelines recommended examination of two samples per patient to ensure correct 
evaluation[1]. A second PVSA was recommended to counter uncertainty associated with the pre-examination 
phase, e.g. men not following pre-examination instructions properly, insufficient collection of the whole 
sample and non-compliance with instructions for transport to the laboratory.  
A number of publications have since considered that a single sample is sufficient [4 18 20 41-43]. After 
assessing the supporting evidence, the Professional Bodies agree that assessment of a single sample is 
appropriate provided there is strict adherence to instructions for production, delivery and time to 
examination, to minimise any adverse effects on the sample. Optimally, sample production on-site provides 
the best control over delivery and time, although this still relies on the man abiding by pre-assessment and 
actual collection instructions, which introduces uncertainty.  
The Professional Bodies support the move towards examination of a single PVSA to establish operative success 
when the process is tightly controlled, complying with all recommendations and methodology guidance listed 
in this document. It must be noted that this is entirely dependent on ensuring that specimen acceptance 
criteria are fully complied with and that this is limited by the patient’s own interpretation of what constitutes 
complete sample collection. In many areas of medicine it is rare that a ‘diagnosis’ is made without 
confirmation. As such, people should be able to freely request a second confirmatory sample and this right 
should not be fettered.   
The recommendation is Grade C due to limited evidence but having the backing of experts and the three 
professional bodies. 
Recommendation 5: Assessment of a single sample is acceptable to confirm vasectomy success if all 
recommendations and laboratory methodology are met and no sperm are observed. Clearance can then be 
given.  
 “SPECIAL CLEARANCE”  
Persistent non-motile sperm in initial PVSA samples is not uncommon, with studies reporting up to 33% non-
azoospermic samples at 3 months, and 10% of ejaculates containing non-motile sperm at 6 months[16 44]. In 
one prospective study, the median time to azoospermia was 10 weeks, with most men (93%) being 
azoospermic by 20 weeks[25]. Similarly, sperm have been reported to temporarily reappear in ejaculates 12 
months after surgery, despite previous sperm-free ejaculates[9]. 
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In another prospective long-term follow up study, over 1000 men submitted semen samples at one, two, and 
three years PV[3]. Twenty of these men had non-motile sperm detected in their samples, but there were no 
reports of unwanted pregnancies in the partners of these men. Discussion in the literature has suggested that 
the risk of pregnancy occurring from men whose previous samples show non-motile sperm present is small[39] 
and probably no more than the risk of pregnancy after two azoospermic semen samples, as a result of 
spontaneous recanalisation [3 45]. The risk of fertility for a PVSA sample showing azoospermia has been 
estimated at about 1 in 2,000[13]. It has been suggested that repeat ejaculates 7 months after surgery are 
probably unnecessary because pregnancy is very unlikely to occur [39 46]. 
For pathology tests in general, whenever a test is equivocal, in this case when sperm are observed, then a 
repeat test is requested which must comply with all Recommendations.  A vitality test can also be performed 
on the sperm to assess whether they are alive or not, but a non-motile sperm will not be able to fertilise an 
oocyte in-vivo. 
If a physician wishes to grant ‘special clearance’ to a man who repeatedly has reports of sperm in his PVSA, 
then he should be aware of the medico-legal consequences should a motile sperm be produced.  
Current international reviews show a variance in the maximum number of non-motile sperm that are allowed 
to be detected before special clearance may be given, with the American Urological Association (AUA) in the 
USA and FSRH in the UK stating <100,000 sperm/ml [2 31]. In practice, accuracy demands that this is the limit, 
as it is not possible to reach the required levels of accuracy for a lower value by anything other than the fixed-
depth slide method [47]. 
Laboratories must be able to validate & verify that their reported counts are accurate and what their detection 
accuracy or range may be, accepting there will be a measure of uncertainty. Figures beneath 100,000/ml lack 
robust evidence that they are necessary as in general the counting methods employed in studies suggesting 
them have not had the low-count stringent accuracy required. The Professional Bodies therefore believe, that 
with recognition of the true accuracy of counting methods in the published literature, <100,000 sperm/ml is a 
prudent figure to base clearance upon, with due note that this is at the limit of count accuracy of these 
methods. 
It should be noted that no result can guarantee sterility, with a number of rare reported cases of men with no 
detectable sperm still going on to have proven paternity [14]. 
The recommendation is Grade B due being based on evidence from a number of robust though limited studies, 
but no ability to ever be absolute. It has the backing of experts and the three Societies. 
Recommendation 6: The level for special clearance should be <100,000/ml non-motile sperm. Special 
clearance cannot be provided if any motile sperm are observed and should only be given after assessment of 
two samples in full accordance with these guidelines. 
CONCLUSIONS & IMPLEMENTATION 
The Professional Bodies expect that implementation of these guidelines can occur from the date of publication 
and should be completed within 12 months. 
For all situations, where there is a deviation from compliance with these guidelines, for example if a test has 
been performed before 12 weeks and 20 ejaculations, this should be clearly noted on any report provided, 
with appropriate reference suggestion for requesting a fresh samples to test correctly within the guidelines. If 
departing from the guidelines, individuals and laboratories should be aware of the standards of best practice 
and potential medico-legal consequences. 
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